Sign In
Buy NEO
$15.29
-0.590 (-3.72%)
At Close: Jul 31, 2026
Is NeoGenomics Inc (NEO) a Bargain After 3.7% Drop? GF Value Says Undervalued
07:41pm, Friday, 31'st Jul 2026
On July 31, 2026, NeoGenomics Inc (NEO) shares fell 3.7% to $15.29, reflecting a mixed price performance amid broader market movements. The stock has traded wit
NeoGenomics (NASDAQ:NEO) Reaches New 12-Month High After Earnings Beat
02:01am, Thursday, 30'th Jul 2026
NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) reached a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $16.10 and la
NeoGenomics Q2 Earnings Call Highlights
06:07pm, Tuesday, 28'th Jul 2026
NeoGenomics NASDAQ: NEO raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testi
NeoGenomics Reports Second Quarter 2026 Results
04:05pm, Tuesday, 28'th Jul 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
American Capital Management Inc. Decreases Stock Holdings in NeoGenomics, Inc. $NEO
04:20am, Tuesday, 28'th Jul 2026
American Capital Management Inc. lowered its position in shares of NeoGenomics, Inc. (NASDAQ: NEO) by 3.2% in the first quarter, according to the company in its most recent Form 13F filing with the Se
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
08:15am, Thursday, 23'rd Jul 2026
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
07:57am, Tuesday, 21'st Jul 2026
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
05:23pm, Monday, 20'th Jul 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS.
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
09:00am, Wednesday, 15'th Jul 2026
CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the developm
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
07:05am, Thursday, 09'th Jul 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
07:05am, Tuesday, 07'th Jul 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
07:05am, Thursday, 25'th Jun 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
09:00am, Tuesday, 23'rd Jun 2026
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
08:10am, Friday, 19'th Jun 2026
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
05:42pm, Wednesday, 17'th Jun 2026
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
